Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.
For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen
Baptist Health South Florida/Miami Cancer Institute, Miami, Florida, United States
School of phamaceutical, Tsinghua University, Beijing, Beijing, China
Biotherapeutic Department, Chinese PLA General Hospital, Beijing, China
Hackensack University Medical Center, Hackensack, New Jersey, United States
Georgetown University Medical Centre, Washington, District of Columbia, United States
IRCCS Azienda Ospedaliero - Universitaria di Bologna, Bologna, Italy
University of Illinois, Chicago, Illinois, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
The Ohio State University, Columbus, Ohio, United States
Shanghai Pudong Hospital, Fudan University Affiliated Pudong Medical Center, Shanghai, Shanghai, China
The Affiliated People's Hospital of Ningbo University, Ningbo, Zhejiang, China
Memorial Sloan Kettering, New York, New York, United States
University of Alabama at Birmingham, Birmingham, Alabama, United States
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Shanghai Pudong Hospital, Fudan University Affiliated Pudong Medical Center, Shanghai, Shanghai, China
Lucile Packard Children's Hospital, Palo Alto, California, United States
M D Anderson Cancer Center, Houston, Texas, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.